Success! You're on the list.

Success! You're on the list.

Peter Thiel-backed Lindus Health shakes up antiquated clinical trials sector, raises $18M

Lindus Health team
Picture credits: Lindus Health

Lindus Health, a startup based in London, has successfully raised $18 million in Series A funding from investors, including Creandum, known for backing Spotify, and PayPal co-founder Peter Thiel, who had also supported their previous round. Additional participation came from existing investors, namely firstminute, Seedcamp, Hambro Perks, and Amino Collective.

Enables faster end-to-end clinical trials

Notably, Creandum’s involvement goes beyond financial support as they will also be joining Lindus Health’s board. This injection of funds will fuel Lindus Health’s ambitions to expand its approach to conducting rapid and advanced clinical trials for various health conditions, such as depression, diabetes, and insomnia. Further, as part of its growth strategy, the company is actively recruiting for a variety of key roles in business development, clinical operations, and operations management.

Commenting on the raise, Michael Young, Co-Founder of Lindus Health, said: “Clinical trials are the biggest bottleneck to improving human health. We deliver clinical trials three times faster than the industry standard, working with biotech pioneers to get new treatments to patients more quickly. Through this latest raise, we will be further investing in our technology platform so that we can deliver clinical trials in completely new ways.”

Meri Beckwith, Co-Founder of Lindus Health, said: “The antiquated clinical trials industry is holding back healthcare. Everyone suffers from the status quo, especially patients, who must wait decades and pay higher prices for new treatments. We’re excited to accelerate the pace and scale of our work with high-growth companies that will be responsible for the next wave of breakthrough treatments. This investment will help us achieve our vision of creating a much more agile and productive life sciences industry, for the benefit of all.”

Fredrik Cassel, General Partner at Creandum, said: “When we first met Michael, Meri and the rest of the Lindus Health team, we knew their approach to disrupting the clinical trials industry would be the right one. With a tech-first, AI-powered, end-to-end offering, Lindus Health is building unparalleled efficiency and quality into what has always been a manual process. We were blown away by the work Lindus is already doing across the US, UK and Europe with stellar customer feedback and references. The potential Lindus has on improving the world’s health is vast and we are excited to join them on this journey.”

3x faster clinical trials

Founded by Meri Beckwith, Nik Haldimann, and Michael Young in 2021, Lindus Health runs clinical trials three times faster than the old-fashioned industry standard. It brings treatments to patients more quickly. Clinical trials are the biggest bottleneck to advances in healthcare and by removing this constraint we aim to improve health for everyone. Lindus does this by using its industry-first platform that can manage a trial from start to finish.

Further, the UK-based startup utilises its technology platform and machine learning to execute clinical trials from start to finish, helping treatments to reach patients more quickly to improve and extend the lives of those living with chronic illnesses.

As of now, Lindus Health has already delivered over 80 trials across the UK, US, and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome, and insomnia.

Additionally, the British healthtech has also worked with 20,000 patients to find new treatments for chronic conditions and improve lives. It has a team of 40 from companies including Meta, Google, Oxford University, and Optum Health, working across the US, UK, and EU.

Related Posts

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you